Torne-se Associado
P-BIO_icon-site
Torne-se Associado
Linkedin Twitter Facebook Youtube Instagram

Associados

Categoria:

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

P-BIO October 15, 2023 - cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening...

Saiba Mais

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

P-BIOOctober 15,  2023- FRUZAQLA is the First Targeted Therapy Approved for Metastatic Colorectal Cancer (mCRC)...

Saiba Mais

TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

P-BIO October 26, 2023TZIELD® Phase 3 data presented at ISPAD shows potential to slow the...

Saiba Mais

U.S. Food and Drug Administration Approves BioMarin’s VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia

P-BIO October 26, 2023Expanded Indication in the U.S. Now Includes Children of all ages with...

Saiba Mais

PeekMed expands into the US with a new subsidiary and a new product

Image: Jornal de Negócios P-BIO October 24, 2023PeekMed announces the establishment of PeekMed LLC, its formal...

Saiba Mais

U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

Imagem: Pixabay P-BIO 13 de outubro de 2023 Approval of oral, once-daily VELSIPITY based on...

Saiba Mais
Linkedin Twitter Facebook Youtube